| Literature DB >> 27575370 |
Kamil Chwojnicki1, Ewa Król2, Łukasz Wierucki3, Grzegorz Kozera1, Piotr Sobolewski4, Walenty M Nyka1, Tomasz Zdrojewski3.
Abstract
BACKGROUND: The presence of chronic kidney disease (CKD) is an indicator of a worse long-term prognosis in patients with ischemic stroke (IS). Unfortunately, not much is known about renal function in the population of post-IS subjects. The aim of our study was to assess the prevalence of renal damage and impaired renal function (IRF) in the population of post-IS subjects.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27575370 PMCID: PMC5019346 DOI: 10.1371/journal.pone.0159775
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Description of recruitment to the study.
| Status description | N | % |
|---|---|---|
| All patients hospitalized due to IS in selected stroke units | 660 | 100,0 |
| Respondents deceased during hospitalization | 63 | 9.5 |
| All subjects surviving hospitalization in selected centers | 597 | 90,5 |
| Respondents deceased between the end of hospitalization and first visit | 67 | 10,2 |
| All patients provided informed consent | 352 | 53,3 |
| Visits I, II or I, II, III (blood and urine testing performed) | 306 | 46,4 |
| Visits I and II, no blood and urine testing (samples not properly analyzed by central laboratory due to pre-laboratory or laboratory errors) | 29 | 4,4 |
| Visit I only, no blood and urine sampling (no informed consent for sampling) | 17 | 2,6 |
| Refusals | 100 | 15,2 |
| Wrong addresses | 55 | 8,3 |
| No information | 23 | 3,5 |
Baseline characteristics and comorbidities of surviving and non-surviving subjects with ischemic stroke (data derived from hospitalization period).
| Surviving subjects (N = 597) | Non-surviving subjects (N = 130) | |||||||
|---|---|---|---|---|---|---|---|---|
| All | Women | Men | All | Women | Men | |||
| [years] | 69.94 ±12.42 | 73.96 ±11.93 | 66.49 ±11.78 | 74,62 ±11.74 | 76,54 ±9.59 | 71,69 ±14.09 | ||
| [pct] | 11.27 ±4.98 | 11.04 ±4.84 | 11.43 ±5.08 | 16.30 ±4.85 | 16.84 ±5.19 | 15.48 ±4.23 | ||
| μmol/L | 84.86 ±25.64 | 90.17 ±23.00 | 79.56 ±28.29 | 114.04 ±40.66 | 123.76 ±35.17 | 99.01 ±43.36 | ||
| mL/min/ 1.73m2 | 78.21 ±21.58 | 70.29 ±21.40 | 84.71 ±21.70 | 70.02 ±26.54 | 62.35 ±27.24 | 82.78 ±22.58 | ||
| mL/min/ 1.73m2 | 73.94 ±19.47 | 67.10 ±20.52 | 79.55 ±18.44 | 68.28 ±21.37 | 60.43 ±22.80 | 74.33 ±16.67 | ||
| [%] | 81.48 | 83.75 | 79.58 | 81.23 | 87.27 | 72.07 | ||
| [%] | 31.05 | 34.38 | 28.27 | 31.92 | 35.00 | 27.24 | ||
| [%] | 60.11 | 61.88 | 58.64 | 69.86 | 68.18 | 72.41 | ||
| [%] | 58.24 | 62.30 | 53.75 | no data | ----- | ----- | ||
| [%] | 27.64 | 32.50 | 23.56 | 53.42 | 54.55 | 51.72 | ||
| [%] | 59.26 | 35.00 | 79.58 | 55.07 | 46.82 | 67.59 | ||
eGFR—estimated glomerular filtration rate; MDRD—modification of diet in renal diseases formula; CKD-EPI—Chronic Kidney Disease Epidemiology Collaboration formula; BMI—body mass index; MRs—modified Rankin scale;
1—P<0.05 survivors vs deaths (all)
2—P<0.05 women vs men (surviving)
3—P<0.05 women vs men (non-surviving)
Fig 1Distribution of stage 3 to 5 of chronic kidney disease on the basis of glomerular filtration rate measured according to MDRD and CKD-EPI formulas in post-IS subjects.
Fig 2Frequency of diminished kidney function (eGFR < 60 mL/min/1.73m2) estimated by MDRD and CKD-EPI formulas and albuminuria measured as urine albumin to creatinine ratio (ACR) in survivors with ischemic stroke according to IS etiology.
Univariate analysis for potential risk factors of chronic kidney disease in examined population of surviving subjects with ischemic stroke (data from nurses visits).
| ACR≥30 mg/g (%) | MDRD <60mL/min/1.73m2 (%) | CKD-EPI <60mL/min/1.73m2 (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| All | M | W | All | M | W | All | M | W | ||
| 12.62 | 13.33 | 10.71 | 2.78 | 0.00 | 10.00 | 1.85 | 0.00 | 6.67 | ||
| ≥65 | 35.87 | 30.68 | 41.05 | 27.27 | 16.67 | 36.11 | 35.86 | 21.11 | 48.15 | |
| <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | ||
| Primary /vocational | 33.16 | 27.84 | 38.39 | 20.9 | 10.31 | 30.77 | 26.37 | 12.37 | 39.42 | |
| Secondary /higher | 17.17 | 15.15 | 21.21 | 14.71 | 7.14 | 31.25 | 18.63 | 10.00 | 37.50 | |
| <0.01 | 0.06 | 0.07 | 0.19 | 0.48 | 0.96 | 0.14 | 0.63 | 0.84 | ||
| 3–5 | 36.36 | 27.27 | 47.27 | 25.37 | 15.15 | 35.29 | 32.84 | 18.18 | 47.06 | |
| 0–2 | 20.00 | 18.28 | 22.81 | 11.69 | 4.12 | 24.56 | 14.94 | 6.19 | 29.82 | |
| <0.01 | 0.18 | <0.01 | <0.01 | 0.01 | 0.19 | <0.01 | 0.02 | 0.04 | ||
| MMSE≥24 | 21.34 | 21.00 | 21.88 | 14.37 | 5.88 | 27.69 | 19.16 | 7.84 | 36.92 | |
| MMSE<24 | 31.68 | 24.53 | 40.43 | 25.45 | 14.55 | 36.36 | 31.82 | 18.18 | 45.45 | |
| 0.06 | 0.62 | 0.04 | 0.02 | 0.07 | 0.31 | 0.02 | 0.05 | 0.34 | ||
| No | 22.45 | 18.75 | 31.25 | 16.67 | 9.38 | 27.27 | 22.22 | 9.38 | 40.91 | |
| Yes | 28.57 | 23.66 | 34.58 | 19.05 | 8.82 | 31.03 | 24.21 | 11.76 | 38.79 | |
| 0.38 | 0.55 | 0.79 | 0.68 | 0.92 | 0.72 | 0.76 | 0.70 | 0.85 | ||
| No | 21.94 | 22.03 | 21.79 | 16.1 | 9.24 | 25.58 | 20.98 | 11.76 | 33.72 | |
| Yes | 39.56 | 24.44 | 55.56 | 23.76 | 8.16 | 38.46 | 29.7 | 10.02 | 48.08 | |
| <0.01 | 0.74 | <0.01 | 0.07 | 0.82 | 0.11 | 0.09 | 0.77 | 0.09 | ||
| No | 32.08 | 25.00 | 42.86 | 19.83 | 10.61 | 32.00 | 27.59 | 12.12 | 48.00 | |
| Yes | 24.86 | 21.21 | 29.63 | 17.89 | 7.84 | 29.55 | 21.58 | 10.78 | 34.09 | |
| 0.19 | 0.57 | 0.14 | 0.67 | 0.54 | 0.76 | 0.23 | 0.79 | 0.11 | ||
| No | 29.89 | 23.26 | 36.36 | 22.58 | 8.94 | 35.42 | 30.11 | 12.20 | 50.00 | |
| Yes | 26.50 | 22.50 | 32.91 | 16.9 | 8.89 | 27.78 | 21.13 | 8.89 | 33.33 | |
| 0.56 | 0.92 | 0.70 | 0.24 | 0.99 | 0.35 | 0.12 | 0.55 | 0.06 | ||
| <30 kg/m2 | 27.14 | 23.36 | 31.52 | 16.67 | 8.18 | 26.00 | 22.38 | 10.91 | 35.00 | |
| ≥30 kg/m2 | 26.87 | 21.74 | 38.10 | 20.59 | 6.25 | 55.00 | 22.06 | 8.33 | 55.00 | |
| 0.97 | 0.83 | 0.56 | 0.46 | 0.67 | 0.01 | 0.96 | 0.62 | 0.09 | ||
| smokers (active/ex) | 22.94 | 22.66 | 24.39 | 12.43 | 9.02 | 22.73 | 14.69 | 11.28 | 25.00 | |
| non-smokers | 34.19 | 22.86 | 39.02 | 27.13 | 8.57 | 34.04 | 36.43 | 11.43 | 45.74 | |
| 0.04 | 0.98 | 0.11 | <0.01 | 0.93 | 0.18 | <0.01 | 0.98 | 0.02 | ||
| No | 32.39 | 24.05 | 43.55 | 20.00 | 10.98 | 30.88 | 26.00 | 14.63 | 38.57 | |
| Yes | 22.76 | 21.43 | 24.59 | 17.31 | 6.98 | 30.00 | 21.79 | 8.14 | 39.71 | |
| 0.07 | 0.67 | 0.03 | 0.32 | 0.36 | 0.91 | 0.23 | 0.18 | 0.89 | ||
Stepwise logistic regression models for potential risk factors of chronic kidney disease in examined population of surviving subjects with ischemic stroke (based on results from nurses visits).
| Effect | ACR≥30 [mg/g] | MDRD<60 or CKD-EPI<60 [mL/min/1.73m2] | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| 1.01 | 0.49–2.06 | 0.98 | 3.43 | 1.40–8.36 | 0.01 | |
| 1.37 | 1.10–1.72 | <0.01 | 2.01 | 1.39–2.90 | <0.01 | |
| 0.60 | 0.30–1.18 | 0.14 | 0.87 | 0.37–2.04 | 0.74 | |
| 2.40 | 1.71–2.76 | 0.03 | 1.56 | 0.69–3.50 | 0.28 | |
| 0.83 | 0.41–1.68 | 0.60 | 0.83 | 0.36–1.93 | 0.66 | |
| 2.19 | 1.16–4.15 | 0.02 | 2.59 | 1.74–3.43 | 0.03 | |
| 0.92 | 0.48–1.76 | 0.80 | 0.87 | 0.40–1.90 | 0.73 | |
| --------- | ------------ | ------- | 1.20 | 0.54–2.64 | 0.66 | |
| 0.69 | 0.37–1.27 | 0.23 | 0.68 | 0.32–1.40 | 0.29 | |
| 1.03 | 0.48–2.20 | 0.94 | 1.90 | 0.76–4.76 | 0.17 | |
a P value of <0.05 is considered statistically significant; mRs—modified Rankin scale; MMSE—mini-mental state examination; ACEI—angiotensin-converting-enzyme inhibitor; ARBs—Angiotensin II Receptor Blockers.